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Introduction {#jdi13156-sec-0005}
============

Neonatal diabetes mellitus is a subtype of diabetes with onset within the first 6 months of life. It occurs in approximately one in 90,000--160,000 live births, is an uncommon monogenic disease owing to genetic defects of beta‐cell function and/or mass, and 80% of cases possess a known genetic dysfunction in Europe[1](#jdi13156-bib-0001){ref-type="ref"}. In China, Li *et al.* [2](#jdi13156-bib-0002){ref-type="ref"} reported that the genetic etiology could be determined in 84% (19/23) of Chinese patients with neonatal diabetes mellitus, which was higher than the outcomes from Cao *et al.* [3](#jdi13156-bib-0003){ref-type="ref"} (60%; 15/25). According to the clinical consequences, neonatal diabetes mellitus can be divided into two forms, transient neonatal diabetes mellitus and permanent neonatal diabetes mellitus[4](#jdi13156-bib-0004){ref-type="ref"}. Transient neonatal diabetes mellitus accounts for 50--60% of neonatal diabetes mellitus, which is 28--56.5% in Chinese patients[2](#jdi13156-bib-0002){ref-type="ref"}, [3](#jdi13156-bib-0003){ref-type="ref"}. Transient neonatal diabetes mellitus is generally diagnosed within 1 month after birth (median 6 days), and is characterized by intrauterine growth retardation with a low original dose of insulin for replacement and yields a "Diabetes--Remission--Relapse" natural history, which enters remission after 12 weeks, whereas it might relapse in young adults[5](#jdi13156-bib-0005){ref-type="ref"}. Permanent neonatal diabetes mellitus shows a lifelong disorder without remission.

To date, \>20 genes have been recognized as key elements that cause permanent neonatal diabetes mellitus[6](#jdi13156-bib-0006){ref-type="ref"}, of which mutations in *KCNJ11* and *ABCC8* accounted for 40--60% of all occasions, which was 53.3--68.4% in China[2](#jdi13156-bib-0002){ref-type="ref"}, [3](#jdi13156-bib-0003){ref-type="ref"}. They are separately responsible for Kir6.2 and SUR1 of the adenosine triphosphate‐sensitive potassium channel[6](#jdi13156-bib-0006){ref-type="ref"}. Mutations in the two genes can result in consistent opening of the adenosine triphosphate‐sensitive potassium channel, which induces membrane hyperpolarization and insulin secretion disorder[7](#jdi13156-bib-0007){ref-type="ref"}. Mutation*s* in the insulin gene (*INS*) are the secondary cause (23%)[8](#jdi13156-bib-0008){ref-type="ref"}. Other mutations include *GATA6*,*EIF2AK3*,*GCK*,*PTF1A*,*FOXP3*,*ZFP5*7,*GLIS3*,*PDX1*,*SLC2A2*,*SLC19A2*,*GATA4*,*NEUROD1*,*NEUROG3*,*NKX2‐2*,*RFX6*,*IER3IP1*,*MNX1*,*HNF1B* and *STAT3* [1](#jdi13156-bib-0001){ref-type="ref"}. The overexpression of genes at chromosome 6q24 is the most common cause of transient neonatal diabetes mellitus (OMIM 601410), which encompasses 70% of all cases[9](#jdi13156-bib-0009){ref-type="ref"}. Basic and clinical studies suggest that sulfonylurea can help with the closing of the adenosine triphosphate‐sensitive potassium channel, and improve glycemic control and neurological outcomes[10](#jdi13156-bib-0010){ref-type="ref"}, which was also confirmed in Chinese patients[2](#jdi13156-bib-0002){ref-type="ref"}, [3](#jdi13156-bib-0003){ref-type="ref"}. Thus, molecular diagnosis is vital for accurate diagnosis and prognosis assessment for neonatal diabetes mellitus. Here, we carried out genetic sequencing in four Chinese infants with diabetes, and identified four mutations in the *INS* gene.

Methods {#jdi13156-sec-0006}
=======

Participants {#jdi13156-sec-0007}
------------

Four infants were recruited from the outpatient clinic of Beijing Peking Union Medical College Hospital, Beijing, China, with a diagnosis of diabetes within 1 year‐of‐age and without remission. Our research team has focused on neonatal diabetes mellitus from 2007 to the present; during this time period, 25 patients were diagnosed with neonatal diabetes mellitus (with diabetes onset \<6 months), and all patients underwent genetic testing. Among them, 21 patients carried mutations causing neonatal diabetes mellitus, and three patients harbored mutations in *INS*. Additionally, one person with diabetes onset at 8 months (\>6 months) also carried mutations in *INS*. Thus, four patients were included in the present study. The families were all unrelated and of Chinese descent. Written consent was obtained from responsible family members. All four cases had no family history of diabetes and were islet autoantibody negative, and no neurological abnormalities (such as developmental delay) were detected in their clinical history.

Ethical consideration {#jdi13156-sec-0008}
---------------------

All procedures carried out in studies involving human participants were in accordance with the ethical standards of the Peking Union Medical College Hospital Ethics Committee, and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Genetic analysis {#jdi13156-sec-0009}
----------------

Genomic DNA of the four pedigrees together with the parents of the four probands was isolated from peripheral blood samples and used to screen the mutations in *KCNJ11*,*ABCC8* and *INS* by polymerase chain reaction direct sequencing. All exons of the aforementioned three genes were screened by primer sequences devised by Premier 5 software (Premier company, Canada) (Table [S1](#jdi13156-sup-0001){ref-type="supplementary-material"}). The entire coding sequence of these genes was screened in the four infants by direct sequencing. Polymerase chain reaction products corresponding to abnormal electrophoretic patterns were directly sequenced to characterize nucleotide variants on the ABI 377 automated sequencer (Perkin‐Elmer Corp., Foster City, CA, USA). The NCBI BLAST database was then used to identify variants by aligning with reference sequences *ABCC8* (NM_000352), *KCNJ11* (NM_000525) and *INS* (NM_000207). Databases including Exome Variant Server (<http://evs.gs.washington.edu/EVS>), dbSNP database in UCSC genome bank and NCBI (<http://www.ncbi.nlm.nih.gov/snp/>) were used to exclude single nucleotide polymorphisms. Furthermore, the determined variants should not have been present in 100 non‐diabetic healthy controls (blood donors associated with the clinic). Mutations in the parents were detected by targeting sequencing of the affected exons. The functional effects of variants were predicted by PolyPhen2 (<http://genetics.bwh.harvard.edu/pph2/>), SIFT (<http://sift.jcvi.org>) and MutationTaster (<http://www.mutationtaster.org>). The pathogenicity of the mutations was assessed according to the American College of Medical Genetics and Genomics[11](#jdi13156-bib-0011){ref-type="ref"}.

The key variables included sex, age, diabetic onset age and family history of diabetes. Clinical indicators included fasting glucose, fasting C‐peptide and glycated hemoglobin A1c (HbA1c). HbA1c (before and after treatment) was measured using dedicated high‐performance liquid chromatography. Islet cell antibodies were measured using indirect immunofluorescence; glutamic acid decarboxylase and insulinoma‐associated antigen 2 were determined by enzyme‐linked immunosorbent assay (SIEMENS ADVIA Centaur XP, Erlangen, Germany).

Results {#jdi13156-sec-0010}
=======

Four infants were diagnosed with permanent neonatal diabetes mellitus. Among them, the diabetic onset age varied from 12 weeks to 8 months; the birthweight ranged from 2,600 g to 3,300 g. All patients showed diabetic ketoacidosis or marked hyperglycemia, with fasting C‐peptide \<0.5 ng/mL, and were treated with insulin from diabetes diagnosis. After treatment, HbA1c was controlled from 7.3% to 8.4% (Table [1](#jdi13156-tbl-0001){ref-type="table"}).

###### 

Clinical manifestations of the four patients

  Mutations       Location and function                         Sex      Birthweight (g)    Clinical manifestations   Onset age (week)   FBG at onset (mmol/L)   C‐peptide (ng/mL)   Treatment   HbA1c before/after treatment (%)
  --------------- --------------------------------------------- -------- ------------------ ------------------------- ------------------ ----------------------- ------------------- ----------- ----------------------------------
  C96R            A7, affecting disulfide bonds                 Male     3,300 (25--50th)   DKA                       24                 NA                      0.03                Insulin     8.1%/7.5%
  I99_C100insSI   A10‐A11, affecting disulfide bonds            Female   2,600 (3--10th)    DKA                       16                 NA                      0.05                Insulin     9.7%/7.8%
  G32S            B8, affecting disulfide bonds                 Male     2,900 (10--25th)   Hyperglycemia             12                 33                      0.42                Insulin     9.1%/8.4%
  R89C            Cleavage site between A chain and C‐peptide   Female   2,950 (10--25th)   Hyperglycemia             32                 30.32                   0.37                Insulin     8.6%/7.3%

DKA, diabetic ketoacidosis; NA, not available.
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Case 1 was a 1‐year‐old girl with a birthweight of 2,600 g (3--10th). She was diagnosed with diabetes at 4 months after birth and was referred to the hospital because of diabetic ketoacidosis. Biochemical examination showed that the fasting C‐peptide level was very low (0.05 ng/mL). Subsequently, she was treated with basal and preprandial insulin. Case 2 was a 6‐month‐old boy whose birthweight was 2,900 g (10--25th). The diabetes manifested at 3 months after birth. He was sent to the hospital due to hyperglycemia, and was treated with basal and preprandial insulin. He also showed a low fasting C‐peptide level (0.42 ng/mL). Case 3 was a 2‐year‐old boy who had suffered from diabetes since he was aged 6 months, and he had received insulin injections until the study. His birthweight was 3,300 g (25--50th), and his fasting C‐peptide was 0.03 ng/mL. Case 4 had the oldest diabetic onset age (8 months after her birth) of the four patients. Her birthweight was 2,950 g (10--25th), and the fasting C‐peptide was 0.37 ng/mL. Among them, an attempt by case 2 to switch from insulin to oral sulfonylureas failed.

Genetic testing showed four mutations, including one novel (p.I99_C100insSI \[case 1\]) and three previously reported mutations (p.G32S \[case 2\], p.C96R \[case 3\] and p.R89C \[case 4\]; Figure [1](#jdi13156-fig-0001){ref-type="fig"}), and no mutations were found in *KCNJ11* and *ABCC8*. The positions of these mutations in proinsulin are shown in Figure [2](#jdi13156-fig-0002){ref-type="fig"}. The novel mutation, p. I99_C100insSI, caused the insertion of two amino acids (Ser and Ile) into the key position of the disulfide bond in the A chain (A10 and A11). Mutation p.C96R (c.286 T\>C) induced an amino acid change (T\>C) at c.286, which is also located at the site of the disulfide bond. Mutation p. R89C affects the cleavage site between the A chain and C‐peptide. Mutation p.G32S plays a role in affecting proinsulin folding in the endoplasmic reticulum and disulfide bonds[12](#jdi13156-bib-0012){ref-type="ref"}. The parents of the four cases had no mutations and no clinical manifestations of diabetes (Figure [3](#jdi13156-fig-0003){ref-type="fig"}).

![Sequencing chromatogram of the mutations in the *INS* gene. Arrows indicate the changed nucleotide base.](JDI-11-578-g001){#jdi13156-fig-0001}

![Diagram representing the human proinsulin molecule showing the location of mutations causing neonatal diabetes. Blue, insulin A chain; dark yellow, insulin B chain; yellow, C‐peptide; blank, basic residues that are the cleavage site for conversion from proinsulin to insulin; green, mutations in *INS*; boxes, mutations found in the present study, in which the red box was the novel mutation found in the study.](JDI-11-578-g002){#jdi13156-fig-0002}

![Pedigree of families of the four infants in the present study. Squares represent male family members, whereas circles represent female family members. Black symbols represent individuals with diabetes, and blank symbols represent normal individuals. Arrows indicate probands in the families. Variant carriers presented as N, normal allele; M, mutation.](JDI-11-578-g003){#jdi13156-fig-0003}

Of the four variants, three were predicted to be deleterious by three bioinformatics tools (p. C96R, p. R89C and p. G32S; Table [2](#jdi13156-tbl-0002){ref-type="table"}), and all of them were considered pathogenic in a previous study[13](#jdi13156-bib-0013){ref-type="ref"}, [14](#jdi13156-bib-0014){ref-type="ref"}. Furthermore, the novel mutation, p.I99_C100insSI, was considered as "likely pathogenic" based on the American College of Medical Genetics and Genomics [11](#jdi13156-bib-0011){ref-type="ref"}: PM2 (absent from controls in ESP, 1,000 Genomes or ExAC), PM4 (variant affecting protein length), PP1 (cosegregation with permanent neonatal diabetes mellitus in family members) and PP4 (the clinical phenotype is gene‐specific). Phyre2 (<http://www.sbg.bio.ic.ac.uk/~phyre2/html/page.cgi?xml:id=index>) was used to predict the structure of the proteins with missense mutations. We found no differences in the structure of wild‐type and mutant‐type mutations p. R89C and p.C96R; however, structural damage was yielded by mutation p. G32S (Figure [4](#jdi13156-fig-0004){ref-type="fig"}).

###### 

Prediction of the missense mutations in *INS* found in the present study

  Mutations   SIFT              PolyPhen‐2                                MutationTaster
  ----------- ----------------- ----------------------------------------- -----------------
  p.C96R      Deleterious (0)   Probably damaging with a score of 0.993   Disease‐causing
  p.R89C      Deleterious (0)   Probably damaging with a score of 0.987   Disease‐causing
  p.G32S      Deleterious (0)   Probably damaging with a score of 1.000   Disease‐causing
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![Structure modeling of wild‐type and mutant proinsulin (p. G32S). The red circles indicate the amino acid residue of wild‐type and mutant proinsulin.](JDI-11-578-g004){#jdi13156-fig-0004}

Discussion {#jdi13156-sec-0011}
==========

In the present study, four patients were diagnosed with hyperglycemia during their first year of life and have been treated with insulin since diagnosis. There was no history of familial diabetes. Based on the age of onset of diabetes, negative autoantibodies and persistent hyperglycemia, they were diagnosed with permanent neonatal diabetes mellitus. Because up to 90--95% of patients with neonatal diabetes mellitus caused by *KCNJ11* and *ABCC8*can be successfully transitioned from insulin therapy to sulfonylureas[1](#jdi13156-bib-0001){ref-type="ref"}, one of the patients was treated with oral sulfonylureas, but it was not successful. Thus, we carried out genetic testing focusing on the most common genes (*ABCC8*,*KCNJ11* and *INS*) causing permanent neonatal diabetes mellitus, and discovered four mutations in *INS*, one of which was novel and was considered to cause permanent neonatal diabetes mellitus.

*INS* encodes preproinsulin, which includes 110 amino acids, and then preproinsulin forms proinsulin through cleavage of the signal peptide in the endoplasmic reticulum in beta‐cells[1](#jdi13156-bib-0001){ref-type="ref"}. Furthermore, the folding action of proinsulin is managed, and three native disulfide bonds (A6‐A11, B7‐A7 and B19‐A20) are formed before the cleaving of C‐peptide[12](#jdi13156-bib-0012){ref-type="ref"}, [15](#jdi13156-bib-0015){ref-type="ref"}. The mutation in *INS* causing hyperinsulinemia was first reported in 1983 by Tager *et al.* [16](#jdi13156-bib-0016){ref-type="ref"}, and then, many researchers proceeded to identify mutations in *INS* by genome technology (e.g., microarray and sequencing). To date, \>50 *INS* gene mutations (grch37.ensembl.org/) have been identified to cause neonatal diabetes mellitus. A previous study showed that cysteine‐correlated mutations, which introduce or remove a cysteine, lead to pancreatic beta‐cell dysfunction and diabetes, whereas non‐cysteine‐associated mutations might impair the efficiency of chain combination[15](#jdi13156-bib-0015){ref-type="ref"}.

The novel mutation found in the present study, p. I99_C100insSI, is considered "likely pathogenic," which inserted amino acids Ser and Ile between p. I99 and p.C100 in the molecular structure of insulin. The mutation is located at the disulfide bonds (A11); thus, we supposed that the insertion mutation damaged the disulfide bond of the A chain, resulting in permanent neonatal diabetes mellitus. However, molecular biology testing is required to elucidate the function of the mutation. The patient carrying this mutation showed the lowest birthweight and significantly reduced fasting C‐peptide levels in addition to other typical clinical performance of neonatal diabetes mellitus, indicating that this mutation might lead to more severe destruction of beta‐cell function.

B8 glycine has a positive dihedral angle, which prevents L‐amino acids. The L‐amino acids could lead to the rotation of B1--B8, thus turning B7 away from A7[13](#jdi13156-bib-0013){ref-type="ref"}. That is, the substitution of the amino acid (G32S) presumably destabilizes the thermodynamic stability of the molecule and further affects the disulfide bond, which ultimately leads to beta‐cell apoptosis by impairing proinsulin folding and severe endoplasmic reticulum stress[12](#jdi13156-bib-0012){ref-type="ref"}, [13](#jdi13156-bib-0013){ref-type="ref"}, [17](#jdi13156-bib-0017){ref-type="ref"}. Additionally, the glycine residue is conserved within insulin‐like growth factors and is unchanged in *INS* sequences[13](#jdi13156-bib-0013){ref-type="ref"}, suggesting that this mutation was likely pathogenic. In line with the results, the mutation found in the present study was considered pathogenic and cosegregated with clinical phenotypes of permanent neonatal diabetes mellitus within the family. Furthermore, Phyre2 predicts structural damage from this mutation.

Mutation p.C96R caused the changeable amino acid T\>C at c.286 in the *INS* gene. This mutation is believed to cause permanent neonatal diabetes mellitus, because of its disruption in normal disulfide bonds[14](#jdi13156-bib-0014){ref-type="ref"}, [18](#jdi13156-bib-0018){ref-type="ref"}. Its pathogenicity was supported by the three functional prediction software programs, SIFT (0), PolyPhen‐2 (0.993) and MutationTaster (disease‐causing), and American College of Medical Genetics and Genomics standards: PM1 (the position locates in the hot spots for mutations in *INS* gene), PM2 (absent from controls in ESP, 1,000 Genomes or ExAC), PM5 (missense mutation leads to amino acid substitution, and the mutation at the same locus has been confirmed as pathogenic) and PP3 (pathogenicity was confirmed by three bioinformatics tools).

R89C was another mutation in *INS* found in the present study. The mutation caused the changeable amino acid C\>T at c.265 in *INS*. The mutation influences the proteolytic processing of proinsulin and attracts an additional exposed cysteine residue at the site in proinsulin sequences, and is considered as a transition at CpG dinucleotides[19](#jdi13156-bib-0019){ref-type="ref"}. The pathogenicity of the mutation causing permanent neonatal diabetes mellitus has been reported[13](#jdi13156-bib-0013){ref-type="ref"} and was confirmed by three different software programs: SIFT (0), PolyPhen‐2 (0.987) and MutationTaster (disease‐causing).

All four mutations were de novo in the families, which was in line with the previous study from Edghill *et al.* [8](#jdi13156-bib-0008){ref-type="ref"}, who speculated that the majority (80%) of patients with *INS* gene mutations were sporadic cases that resulted from de novo mutations.

Previous studies have suggested that permanent neonatal diabetes mellitus caused by *INS* mutations within 6 months after birth accounts for 12--20% of permanent neonatal diabetes mellitus, but recent studies showed that there were also reports about neonatal diabetes mellitus with diabetes occurring up to 6 months‐of‐age, albeit at a reduced frequency[20](#jdi13156-bib-0020){ref-type="ref"}. In the present study, one of the patients diagnosed with diabetes in her 8 months of life carried the mutation p. R89C in *INS*. The antibody related to type 1 diabetes was negative, and the C‐peptide was very low. This is the first case report of permanent neonatal diabetes mellitus caused by the R89C mutation in *INS* in China. The results suggested that genetic screening was required, even in patients with older diabetic onset age (\>6 months), especially with clinical manifestations of permanent neonatal diabetes mellitus.

Patients with permanent neonatal diabetes mellitus usually presented with diabetic ketoacidosis or marked hyperglycemia, and are not associated with beta‐cell autoantibodies. The C‐peptide levels were low, and lifelong insulin therapy in replacement dose was required. Usually, patients require insulin 0.6--0.8 U/kg/day, which is similar to type 1 diabetes (initial dosage: 0.4--0.5 U/kg/day, prepuberty: 0.7--1.0 U/kg/day). All of these features suggest that most patients are insulin‐dependent. Most of the patients had poor glucose control after insulin treatment, and the possible reasons were as follows: (i) insulin secretion was deficient due to *INS* gene mutation; and (ii) in order to meet growth and development milestones, and avoid hypoglycemia, a loose target was set. Among them, patients with mutations at p.G32 had worse glycemic control (HbA1c 8.0\~9.0%) than the other positions (median HbA1c was 7.9%)[13](#jdi13156-bib-0013){ref-type="ref"}. Structural damage might help explain the phenomenon, and close monitoring during treatment is vital in patients carrying mutations located at B8. There might be other reasons to explain the heterogeneous clinical manifestations. Additionally, participants with permanent neonatal diabetes mellitus showed low birthweight (2.8 kg)[13](#jdi13156-bib-0013){ref-type="ref"}, which is consistent with the present study, where patients also showed low birthweight (2.9 kg, 10--25th).

In conclusion, we discovered one novel mutation in *INS*, p.I99_C100insSI, which was likely to cause permanent neonatal diabetes mellitus. It is predicted that the substitution mutation, p.G32, might lead to more severe hyperglycemia because of structural destruction. Additionally, because *INS* mutations are another common cause of neonatal diabetes mellitus, patients with ineffective treatment with sulfonylureas should be particularly concerned with the detection of this gene, especially for diabetes patients who were diagnosed before the age of 12 months.
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